Mechanism of activation-induced cell death of T cells and regulation of FasL expression

Critical Reviews in Immunology

Volumn 34, Issue 4, 2014, Pages 301-314

  Arakaki, Rieko ^a   Yamada, Akiko ^a   Kudo, Yasusei ^a   Hayashi, Yoshio ^a   Ishimaru, Naozumi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

AICD; Autoimmunity; Fas; FasL; Peripheral tolerance; T cells

Indexed keywords

CYTOKINE; FAS LIGAND; FAS ANTIGEN;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DEATH; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM DISEASES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS;

EID: 84902530588     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2014009988     Document Type: Article

References (135)

1. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010;10(11):797-803.
2. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772-82.
3. Rammensee HG, Kroschewski R, Frangoulis B. Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. Nature. 1989;339(6225):541-4.
4. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532-42.
5. Sakaguchi S, Miyara M, Costantino CM, Hafer DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490-500.
6. Kuklina EM: Molecular mechanisms of T-cell anergy. Biochemistry (Mosc). 2013;78(2):144-56.
7. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80(2):131-7.
8. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003;193:70-81.
9. Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004;1(3):186-92.
10. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008;66(1):52-64.
11. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407(6805):789-95.
12. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH. Te CD95 receptor: apoptosis revisited. Cell. 2007;129(3):447-50.
13. Strasser A, Jost PJ, Nagata S. Te many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180-92.
14. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579-88.
15. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/ FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell. 1996;85(6):803-15.
16. Irmler M, Tome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388(6638):190-5.
17. Medema JP, Scafdi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997;16(10):2794-804.
18. Kang TB, Ben-Moshe T, Varfolomeev EE, Pewzner-Jung Y, Yogev N, Jurewicz A, Waisman A, Brenner O, Haffner R, Gustafsson E, Ramakrishnan P, Lapidot T, Wallach D. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol. 2004;173(5):2976-84.
19. Kang TB, Oh GS, Scandella E, Bolinger B, Ludewig B, Kovalenko A, Wallach D. Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artifcial chromosome-transgenic mice. J Immunol. 2008;181(4):2522-32.
20. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356(6367):314-7.
21. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335(22):1643-9.
22. Davidson WF, Giese T, Fredrickson TN: Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med. 1998;187(11):1825-38.
23. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355-65.
24. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75(6):1169-78.
25. Trambas CM, Grifths GM. Delivering the kiss of death. Nat Immunol. 2003;4(5):399-403.
26. Suzuki A, Enari M, Eguchi Y, Matsuzawa A, Nagata S, Tsujimoto Y, Iguchi T. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J. 1996;15(2):211-5.
27. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol. 2000;278(3):G354-66.
28. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182(5):1223-30.
29. Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med. 1996;183(3):1031-6.
30. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16(1): 39-43.
31. Collette Y, Benziane A, Razanajaona D, Olive D. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL. Blood. 1998;92(4):1350-63.
32. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3(4):269-79.
33. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27: 591-619.
34. Nakayama T, Yamashita M. Te TCR-mediated signaling pathways that control the direction of helper T cell diferentiation. Semin Immunol. 2010;22(5):303-9.
35. Kasibhatla S, Genestier L, Green DR. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem. 1999;274(2):987-92.
36. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11(2):255-60.
37. Wolf BB, Green DR. Suicidal tendencies: apop-totic cell death by caspase family proteinases. J Biol Chem. 1999;274(29):20049-52.
38. Lavrik IN, Krammer PH. Regulation of CD95/ Fas signaling at the DISC. Cell Death Difer. 2012;19(1):36-41.
39. Stegh AH, Schickling O, Ehret A, Scaffidi C, Peterhansel C, Hofmann TG, Grummt I, Krammer PH, Peter ME. DEDD, a novel death efector domain-containing protein, targeted to the nucleolus. EMBO J. 1998;17(20):5974-86.
40. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol. 1998;10(5):545-51.
41. Tibbetts MD, Zheng L, Lenardo MJ. Te death efector domain protein family: regulators of cellular homeostasis. Nat Immunol. 2003;4(5):404-9.
42. Tschopp J, Irmler M, Tome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol. 1998;10(5):552-8.
43. Micheau O, Tome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C, Grutter MG. Te long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002;277(47): 45162-71.
44. Mandal M, Crusio KM, Meng F, Liu S, Kinsella M, Clark MR, Takeuchi O, Aifantis I. Regulation of lymphocyte progenitor survival by the proapop-totic activities of Bim and Bid. Proc Natl Acad Sci U S A. 2008;105(52):20840-5.
45. Masson F, Kupresanin F, Mount A, Strasser A, Belz GT. Bid and Bim collaborate during induction of T cell death in persistent infection. J Immunol. 2011;186(7):4059-66.
46. Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 201; 123(Pt 19):3209-14.
47. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94(4):491-501.
48. Grinberg M, Schwarz M, Zaltsman Y, Eini T, Niv H, Pietrokovski S, Gross A. Mitochondrial carrier homolog 2 is a target of tBID in cells signaled to die by tumor necrosis factor alpha. Mol Cell Biol. 2005;25(11):4579-90.
49. Arnold R, Brenner D, Becker M, Frey CR, Krammer PH. How T lymphocytes switch between life and death. Eur J Immunol. 2006;36(7):1654-8.
50. Tome M, Tschopp J. TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1. Trends Immunol. 2003;24(8):419-24.
51. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693-733.
52. Bellavia D, Campese AF, Vacca A, Gulino A, Screpani I. Notch3, another Notch in T cell development. Semin Immunol. 2003;15(2):107-12.
53. Chen ZJ: Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7(8):758-65.
54. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-7.
55. Kasibhatla S, Genestier L, Green DR. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem. 1999;274(2):987-92.
56. Anel A, Buferne M, Boyer C, Schmitt-Verhulst AM, Golstein P: T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol. 1994;24(10):2469-76.
57. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Diferential regulation of Fas (CD95) versus Fas ligand expression by cyclo-sporin A and FK506. Int Immunol. 1996;8(7): 1017-26.
58. Ranger AM, Oukka M, Rengarajan J, Glimcher LH. Inhibitory function of two NFAT family members in lymphoid homeostasis and T2 development. Immunity. 1998;9(5):627-35.
59. Hodge MR, Ranger AM, Charles de la Brousse F, Hoey T, Grusby MJ, Glimcher LH. Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-defcient mice. Immunity. 1996;4(4):397-405.
60. Baumann S, Hess J, Eichhorst ST, Krueger A, Angel P, Krammer PH, Kirchhof S. An unexpected role for FosB in activation-induced cell death of T cells. Oncogene. 2003;22(9):1333-9.
61. Mages HW, Baag R, Steiner B, Kroczek RA. Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fbroblasts provides a molecular model for the lymphoid cell-specifc efect of cyclosporin A. Mol Cell Biol. 1998;18(12):7157-65.
62. Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD, Glimcher LH. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity. 2000;12(3):293-300.
63. Dzialo-Hatton R, Milbrandt J, Hockett RD, Jr., Weaver CT. Diferential expression of Fas ligand in T1 and T2 cells is regulated by early growth response gene and NF-AT family members. J Immunol. 2001;166(7):4534-42.
64. Brunner T, Kasibhatla S, Pinkoski MJ, Frutschi C, Yoo NJ, Echeverri F, Mahboubi A, Green DR: Expression of Fas ligand in activated T cells is regulated by c-Myc. J Biol Chem. 2000;275(13):9767-72.
65. Janz S. Uncovering MYC's full oncogenic potential in the hematopoietic system. Oncogene 2005;24(22):3541-3.
66. Kasibhatla S, Beere HM, Brunner T, Echeverri F, Green DR. A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc. Curr Biol. 2000;10(19): 1205-8.
67. Raghavendra PB, Pathak N, Manna SK. Novel role of thiadiazolidine derivatives in inducing cell death through Myc-Max, Akt, FKHR, and FasL pathway. Biochem Pharmacol. 2009;78(5): 495-503.
68. Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via down-regulation of c-Myc. J Exp Med. 1999;189(2): 231-9.
69. Chow WA, Fang JJ, Yee JK. Te IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol. 2000;164(7):3512-8.
70. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol. 2003;4(8):733-9.
71. Beverley PC: Primer: making sense of T-cell memory. Nat Clin Pract Rheumatol. 2008;4(1): 43-9.
72. Metz DP, Bottomly K.Function and regulation of memory CD4 T cells. Immunol Res. 1999;19(2-3):127-41.
73. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci U S A. 2004;101(9): 3011-6.
74. Zhu Y, Swanson BJ, Wang M, Hildeman DA, Schaefer BC, Liu X, Suzuki H, Mihara K, Kappler J, Marrack P. Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A. 2004;101(20):7681-6.
75. Mann JJ, Fraker PJ: Zinc pyrithione induces apop-tosis and increases expression of Bim. Apoptosis. 2005;10(2):369-79.
76. Brenner D, Golks A, Becker M, Muller W, Frey CR, Novak R, Melamed D, Kiefer F, Krammer PH, Arnold R. Caspase-cleaved HPK1 induces CD95L-independent activation-induced cell death in T and B lymphocytes. Blood. 2007;110(12):3968-77.
77. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Grifth TS, Green DR, Schoenberger SP. CD4 T-cell help controls CD8 T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434(7029):88-93.
78. Roberts AI, Devadas S, Zhang X, Zhang L, Keegan A, Greeneltch K, Solomon J, Wei L, Das J, Sun E, Liu C, Tuan Z, Zhou JN, Shi Y. Te role of activation-induced cell death in the diferentiation of T-helper-cell subsets. Immunol Res. 2003;28(3):285-93.
79. Janssen O, Sanzenbacher R, Kabelitz D: Regulation of activation-induced cell death of mature T-lymphocyte populations. Cell Tissue Res. 2000;301(1):85-99.
80. Nelson BH: Interleukin-2 signaling and the maintenance of self-tolerance. Curr Dir Autoimmun. 2002;5:92-112.
81. Bosque A, Pardo J, Martinez-Lorenzo MJ, Iturralde M, Marzo I, Pineiro A, Alava MA, Naval J, Anel A. Down-regulation of normal human T cell blast activation: roles of APO2L/ TRAIL, FasL, and c-FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol. 2005;77(4):568-78.
82. Radvanyi LG, Shi Y, Mills GB, Miller RG. Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. Cell Immunol. 1996;170(2):260-73.
83. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8(5):615-23.
84. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480-90.
85. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000;97(21):11445-50.
86. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P: Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000;288(5466):675-8.
87. Zhang J, Bardos T, Shao Q, Tschopp J, Mikecz K, Glant T T, Finnegan A. IL-4 potentiates activated T cell apoptosis via an IL-2-dependent mechanism. J Immunol 2003;170(7):3495-503.
88. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med. 2002;196(7):999-1005.
89. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 1995;86(3):883-9.
90. Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med. 2003;3(6):491-508.
91. Miura Y, Koyanagi Y. Death ligand-mediated apoptosis in HIV infection. Rev Med Virol. 2005;15(3):169-78.
92. Estaquier J, Boutillon C, Georges B, Ameisen JC, Tartar A, Auriault C. A combinatorial peptide library around variation of the human immu-nodefciency virus (HIV-1) V3 domain leads to distinct T helper cell responses. J Pept Sci. 1996;2(3):165-75.
93. Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. Te Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS. 1996;10(1):9-16.
94. Hosaka N, Oyaizu N, Kaplan MH, Yagita H, Pahwa S. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodefciency virus-infected persons. J Infect Dis. 1998;178(4):1030-9.
95. Oyaizu N, Adachi Y, Hashimoto F, McCloskey TW, Hosaka N, Kayagaki N, Yagita H, Pahwa S. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol. 1997;158(5):2456-63.
96. Yoon K, Jeong JG, Kim S. Stable expression of human immunodefciency virus type 1 Nef confers resistance against Fas-mediated apoptosis. AIDS Res Num Retroviruses. 2001;17(2):99-104.
97. van der Vliet HJ, von Blomberg BM, Hazenberg MD, Nishi N, Otto SA, van Benthem BH, Prins M, Claessen FA, van den Eertwegh AJ, Giaccone G, Miedema F, Scheper RJ, Pinedo HM. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol. 2002;168(3):1490-5.
98. Potapinska O, Demkow U. T lymphocyte apop-tosis in asthma. Eur J Med Res. 2009;14 Suppl 4:192-5.
99. Suarez CJ, Parker NJ, Finn PW. Innate immune mechanism in allergic asthma. Curr Allergy Asthma Rep. 2008;8(5):451-9.
100. Vignola AM, Chiappara G, Gagliardo R, Gjomarkaj M, Merendino A, Siena L, Bousquet J, Bonsignore G. Apoptosis and airway infam-mation in asthma. Apoptosis. 2000;5(5):473-85.
101. Spinozzi F, Agea E, Fizzotti M, Bassotti G, Russano A, Droetto S, Bistoni O, Grignani F, Bertotto A. Role of T-helper type 2 cytokines in down-modulation of fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response. FASEB J. 1998;12(15):1747-53.
102. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162(5):1515-20.
103. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P. Te CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multi-forme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol. 2006;154(2):319-24.
104. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7(8):598-605.
105. Ishimaru N, Yanagi K, Ogawa K, Suda T, Saito I, Hayashi Y. Possible role of organ-specifc auto-antigen for Fas ligand-mediated activation-induced cell death in murine Sjogren's syndrome. J Immunol. 2001;167(10):6031-7.
106. Fox RI. Sjogren's syndrome. Lancet. 2005; 366(9482):321-31.
107. Lee BH, Gauna AE, Pauley KM, Park YJ, Cha S. Animal models in autoimmune diseases: lessons learned from mouse models for Sjogren's syndrome. Clin Rev Allergy Immunol. 2012;42(1):35-44.
108. Hayashi Y, Haneji N, Hamano H. Pathogenesis of Sjogren's syndrome-like autoimmune lesions in MRL/lpr mice. Pathol Int. 1994;44(8):559-68.
109. Jabs DA, Prendergast RA: Murine models of Sjogren's syndrome. Adv Exp Med Biol. 1994;350:623-30.
110. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjogren's syndrome in NFS/sld mutant mice. J Immunol. 1994;153(6):2769-777.
111. Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, Noji S, Sugino H, Hayashi Y. Identifcation of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science. 1997;276(5312):604-7.
112. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Diferential regulation of Fas (CD95) versus Fas ligand expression by cyclo-sporin A and FK506. Int Immunol. 1996;8(7): 1017-26.
113. LA OR, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 2009;461(7264):659-63.
114. Oura R, Arakaki R, Yamada A, Kudo Y, Tanaka E, Hayashi Y, Ishimaru N. Induction of rapid T cell death and phagocytic activity by Fas-defcient lpr macrophages. J Immunol. 2013;190(2):578-85.
115. Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, Yagita H, Okumura K, Gregerson DS. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation. 1997;64(8):1107-11.
116. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papof G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275(5302):960-3.
117. Riccioli A, Starace D, D'Alessio A, Starace G, Padula F, De Cesaris P, Filippini A, Ziparo E. TNF-alpha and IFN-gamma regulate expression and function of the Fas system in the seminiferous epithelium. J Immunol. 2000;165(2):743-9.
118. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia. 1999;27(1):62-74.
119. Wang X, Haroon F, Karray S, Martina D, Schluter D. Astrocytic Fas ligand expression is required to induce T-cell apoptosis and recovery from experimental autoimmune encephalomyelitis. Eur J Immunol. 2013;43(1):115-24.
120. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-46.
121. Rieux-Laucat F. Inherited and acquired death receptor defects in human Autoimmune Lymphoproliferative Syndrome. Curr Dir Autoimmun. 2006;9:18-36.
122. Del-Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gomez-Rial J, Roldan E, Morales P, Serrano A, Anel A, Paz-Artal E, Allende LM. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108(4):1306-12.
123. Turbyville JC, Rao VK. Te autoimmune lymph-oproliferative syndrome: A rare disorder providing clues about normal tolerance. Autoimmun Rev. 2010;9(7):488-93.
124. Bleesing JJ, Brown MR, Dale JK, Straus SE, Lenardo MJ, Puck JM, Atkinson T P, Fleisher TA. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoprolif-erative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol. 2001;100(3):314-24.
125. Mohammadzadeh A, Pourfathollah AA, Tahoori MT, Daneshmandi S, Langroudi L, Akhlaghi M. Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients. Rheumatol Int. 2012;32(9):2833-6.
126. Yildir S, Sezgin M, Barlas IO, Turkoz G, Ankarali HC, Sahin G, Erdal ME. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis. Rheumatol Int. 2013;33(10):2637-45.
127. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1998;41(4): 657-62.
128. Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R. Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J Rheumatol. 2000;27(10):2397-405.
129. Tsuzaka K, Matsumoto Y, Sasaki Y, Abe T, Tsubota K, Takeuchi T. Down-regulation of Fas-ligand mRNA in Sjogren's syndrome patients with enlarged exocrine glands. Autoimmunity. 2007;40(7):497-502.
130. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cyto-toxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum. 2003;48(1):174-85.
131. Yildir S, Sezgin M, Barlas IO, Turkoz G, Ankarali HC, Sahin G, Erdal ME. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis. Rheumatol Int. 2013;33(10):2637-45.
132. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteo-arthritis. Arthritis Rheum. 1998;41(4):657-62.
133. Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R. Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J Rheumatol. 2000;27(10):2397-405.
134. Tsuzaka K, Matsumoto Y, Sasaki Y, Abe T, Tsubota K, Takeuchi T. Down-regulation of Fas-ligand mRNA in Sjogren's syndrome patients with enlarged exocrine glands. Autoimmunity. 2007;40(7):497-502.
135. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cyto-toxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum. 2003;48(1):174-85.